New Research Confirms the Benefit of Dario's Integrated, Data-Driven Approach to Health and Chronic Condition Management

新的研究证实了达里奥综合的、数据驱动的健康和慢性病管理方法的好处

NEW YORK, Sept. 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market announced today the publication of a new study in the peer-reviewed journal Frontiers in Endocrinology. The study demonstrates the effectiveness of Dario's cardiometabolic solution for members living with diabetes or prediabetes and depression..

2024年9月10日，全球数字健康市场的领导者DarioHealth Corp.（纳斯达克：DRIO）（“Dario”或“公司”）今天宣布在同行评审的《内分泌学前沿》杂志上发表一项新研究。这项研究证明了达里奥的心脏代谢解决方案对患有糖尿病或糖尿病前期和抑郁症的成员的有效性。。

Approximately 18%–25% of people living with type 2 diabetes (T2D) experience depression1. The co-occurrence of these conditions can lead to poor health outcomes and increased costs for employers and payers, driving demand for integrated solutions to help improve clinical and financial results2,3. Dario's cardiometabolic solution offers members with T2D and prediabetes highly individualized journeys to help manage conditions with a holistic approach that includes integrated mental health support.

大约18%–25%的2型糖尿病（T2D）患者患有抑郁症1。这些疾病的共同发生可能导致健康状况不佳，雇主和付款人的成本增加，推动对综合解决方案的需求，以帮助改善临床和财务结果2,3。Dario的心脏代谢解决方案为患有T2D和糖尿病前期的会员提供高度个性化的旅行，以通过包括综合心理健康支持在内的整体方法来帮助管理疾病。

Data captured from each member's journey, including clinical data such as blood glucose (BG) readings and behavioral data from engagement in digital tools, are integrated in a single, comprehensive data environment to support continuous personalization. This approach allows Dario to better understand the interconnected nature of depression and chronic conditions..

从每个成员的旅程中捕获的数据，包括血糖（BG）读数等临床数据和参与数字工具的行为数据，都集成在一个单一的综合数据环境中，以支持持续的个性化。这种方法使达里奥能够更好地了解抑郁症和慢性病的相互关联性质。。

Dario's capability to integrate data through the pedometer of a smart mobile device or steps being tracked by Apple Health enables a new way to assess the relationship between depressive symptoms and blood glucose levels in individuals with T2D over time, with a particular focus on walking activity as a potential behavioral mediator..

Dario通过智能移动设备的计步器或Apple Health跟踪的步骤整合数据的能力，为评估T2D患者抑郁症状与血糖水平之间的关系提供了一种新方法，特别关注步行活动作为潜在的行为中介。。

'This new research shows the importance of providing a holistic approach to health management. People living with chronic health needs are often trying to manage multiple needs at once, and we believe that Dario's focus on driving healthy behaviors is necessary to improve health and realize better outcomes overall.

“这项新研究表明，提供整体健康管理方法的重要性。患有慢性健康需求的人通常试图同时管理多种需求，我们认为达里奥专注于推动健康行为对于改善健康状况和实现更好的整体结果是必要的。

We are excited to share this data and add new insights to reinforce the impact Dario offers to its members and partners,' said Yifat Hershcovitz, PhD., Vice President of Clinical and Scientific Affairs at Dario. .

Yifat Hershcovitz博士说：“我们很高兴分享这些数据，并增加新的见解，以加强Dario对其成员和合作伙伴的影响。”。，达里奥临床和科学事务副总裁。

'Dario is uniquely positioned to help shed light on the relationship between physical and mental health thanks to the rich volume of data we are able to gather and analyze for insights that benefit our members and our partners. This new research exemplifies the advantages of our data-driven approach to digital health and supports the value of our integrated approach to help employers and health plans to tackle costly and frequently co-morbid conditions,' said Omar Manejwala, M.D., Chief Medical Officer at Dario. .

“由于我们能够收集和分析大量数据，以获得有益于我们的成员和合作伙伴的见解，Dario在帮助阐明身心健康之间的关系方面具有独特的地位。Dario首席医疗官医学博士奥马尔·马内瓦拉（OmarManejwala）说，这项新的研究证明了我们以数据驱动的方法进行数字健康的优势，并支持我们的综合方法的价值，以帮助雇主和健康计划应对昂贵且经常合并症的情况。

Improving Outcomes for Members with Co-Occurring Conditions

改善有共同条件的成员的结果

The new research used retrospective data from 989 users who regularly tracked their steps levels and BG levels for 12 months using Dario's cardiometabolic solution.

这项新的研究使用了989名用户的回顾性数据，这些用户使用Dario的心脏代谢解决方案定期跟踪他们的STEP水平和BG水平12个月。

This study demonstrates how regular walking can mitigate the negative impact of depression on blood glucose levels in individuals with type 2 diabetes or prediabetes, revealing the following:

这项研究表明，定期步行可以减轻抑郁症对2型糖尿病或糖尿病前期患者血糖水平的负面影响，揭示了以下几点：

Dario members who reported depression exhibited higher average BG levels compared to those without depression. In both cases members experienced a significant decrease in BG levels during the initial 4 months of platform usage, followed by a stable period during months 4-12 of the monitoring.A statistically significant association was found between the depression status and BG levels.

与没有抑郁症的人相比，报告抑郁症的Dario成员表现出更高的平均BG水平。在这两种情况下，在平台使用的最初4个月内，成员的BG水平均显着下降，随后在监测的4-12个月内保持稳定。抑郁状态与BG水平之间存在统计学显着关联。

Also, a statistically significant association was found between the depression status and monthly average number of steps.The monthly average number of steps fully mediates the association between self-reported depression and monthly average BG.A significant decrease in monthly average blood glucose for users with monthly average number of steps a day above 400.The new study supports the incorporation of walking into treatment protocols as a cost-effective and accessible intervention strategy to improve glycemic control and alleviate depressive symptoms in people living with T2D and depression..

此外，在抑郁状态和月平均步数之间发现了统计学上显着的关联。月平均步数完全中介了自我报告的抑郁症与月平均BG之间的关联。对于月平均每天步数超过400的用户，月平均血糖显着下降。新研究支持将步行纳入治疗方案，作为一种具有成本效益且易于获得的干预策略，以改善血糖控制并缓解T2D和抑郁症患者的抑郁症状。。

The research was conducted in partnership with Integrative Pain Laboratory, the School of Public Health at the University of Haifa, Israel.

这项研究是与以色列海法大学公共卫生学院综合疼痛实验室合作进行的。

You can read the full study here.

你可以在这里阅读全文。

Refs:

参考文献：

Darwish L, Beroncal E, Sison MV, Swardfager W. Depression in people with type 2 diabetes: current perspectives. Diabetes Metab Syndr Obes. (2018) 11:333–43.Fisher E, Chan J, Nan H, Sartorius N, Oldenburg B. Co-occurrence of diabetes and depression: Conceptual considerations for an emerging global health challenge.

Darwish L，Beroncal E，Sison MV，Swardfager W.2型糖尿病患者的抑郁症：当前观点。糖尿病代谢综合征Obes。（2018）11:333–43.Fisher E，Chan J，Nan H，Sartorius N，Oldenburg B.糖尿病和抑郁症的共同发生：新兴全球健康挑战的概念考虑。

J Affect Disord. (2012) 142 Suppl:S56–66.Egede L, Walker R, Bishu K, Dismuke C. Trends in Costs of Depression in Adults with Diabetes in the United States: Medical Expenditure Panel Survey, 2004–2011. J Gen Intern Med, (2016) 31(6): 615-622.About DarioHealth Corp. .

J影响混乱。（2012）142增刊：S56-66.Egede L，Walker R，Bishu K，Dismuke C.美国成人糖尿病患者抑郁成本的趋势：医疗支出小组调查，2004-2011。J Gen Intern Med，（2016）31（6）：615-622.关于DarioHealth Corp。

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. .

DarioHealth Corp.（纳斯达克股票代码：DRIO）是一家领先的数字健康公司，它通过以用户为中心的多慢性病数字治疗平台，彻底改变了慢性病患者的健康管理方式。。。

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do. .

Dario以用户为中心的平台为人们的健康提供了持续和定制的护理，打破了传统的间歇式医疗保健方法。这种方法使人们能够全面地调整自己的生活方式，以实现可持续的行为改变，提高用户满意度、保留率和结果，并使正确的事情变得容易。

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Dario在全球范围内为医疗计划和其他付款人、自保雇主、护理提供者和消费者提供用户评级较高的解决方案。要了解有关Dario及其数字健康解决方案的更多信息，或要了解更多信息，请访问http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements.

本新闻稿以及DarioHealth Corp.代表和合伙人的声明包含或可能包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。不属于历史事实陈述的陈述可被视为前瞻性陈述。

For example, the Company is using forward-looking statements in this press release when it discusses the effectiveness of Dario's cardiometabolic solution for members living with diabetes or prediabetes and depression, and its ability to improve health and tackle costly and frequently co-morbid conditions.  Without limiting the generality of the foregoing, words such as 'plan,' 'project,' 'potential,' 'seek,' 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'intend,' 'could,' 'estimate' or 'continue' are intended to identify forward-looking statements.

例如，该公司在本新闻稿中使用了前瞻性声明，讨论了达里奥的心脏代谢解决方案对患有糖尿病或糖尿病前期和抑郁症的成员的有效性，以及其改善健康和应对昂贵且经常合并症的能力。在不限制上述一般性的情况下，诸如“计划”、“项目”、“潜力”、“寻求”、“可能”、“意志”、“期望”、“相信”、“预期”、“打算”、“可能”、“估计”或“继续”等词语旨在识别前瞻性陈述。

Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources.

。可能影响公司业绩的因素包括但不限于监管批准、产品需求、市场接受度、竞争产品和价格的影响、产品开发、商业化或技术困难、谈判和贸易的成败、法律、社会和经济风险以及与现有现金资源充足性相关的风险。

Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned.

可能导致或促成公司实际业绩与前瞻性陈述之间差异的其他因素包括但不限于公司向美国证券交易委员会提交的文件中讨论的风险。提醒读者。

DarioHealth Corporate Contact

DarioHealth公司联系人

Mary Mooney VP Marketing mary@dariohealth.com+1-312-593-4280

玛丽·穆尼营销副总裁mary@dariohealth.com+1-312-593-4280

DarioHealth Investor Relations Contact

DarioHealth投资者关系联系人

Kat ParrellaInvestor Relations Managerkat@dariohealth.com +1-315-378-6922

Kat Parrella投资者关系Managerkat@dariohealth.com+1-315-378-6922

Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

标志：https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

SOURCE DarioHealth Corp.

达里奥健康公司。